{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-264177","form_type":"8-K","ticker":"SYBX","cik":"0001527599","company_name":"SYNLOGIC, INC.","filed_at":"2022-10-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.021823+00:00","generated_at":"2026-06-23T02:57:25.332832+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Synlogic reports positive Phase 2 PKU data; SYNB1934 advances to Phase 3 in H1 2023","bullets":["Phase 2 Synpheny-1 study met primary endpoint: 60% response rate with 42% mean Phe reduction among responders.","SYNB1934 showed -34% mean change from baseline in fasting plasma Phe; SYNB1618 showed -20%.","All adverse events mild/moderate, primarily GI; no serious adverse events; 3 discontinuations due to GI AEs.","Company confirms SYNB1934 as Phase 3 candidate; pivotal study expected to begin H1 2023.","Data from 20 adult PKU patients; results consistent with adjunctive use with sapropterin."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-264177","json":"https://secwatch.observer/filing/0001193125-22-264177.json","markdown":"https://secwatch.observer/filing/0001193125-22-264177.md","text":"https://secwatch.observer/filing/0001193125-22-264177.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527599/000119312522264177/0001193125-22-264177-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527599/000119312522264177/d387982d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T02:57:25.332832+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}